Itemgroups: Administration,Laboratory Tests-Hematology,Laboratory Tests-Blood Chemistry,Pregnancy Test,Beta-2 Microglobulin (Serum),Infusion Record Dosimetric Dose - Day 0 and Day 7,Baseline HAMA (human antimurine antibody),Dosimetric Dose,Anti-B1 Dose,Infusion Rate,Vital Signs,Adverse Experiences

Itemgroups: Date of physical examination,B- Symptoms,Physical Examination,Organ/ System,Hematology,Chemistry

Itemgroups: Date of physical examination,B- Symptoms,Physical Examination,Organ/ System,Hematology,Chemistry

Itemgroups: Date of physical examination,Visit Week physical examination,B- Symptoms,Physical Examination,Organ/ System,Visit Week laboratory,Hematology,Chemistry

Itemgroups: Biopsy,Biopsy ,Lymphoma, Non-Hodgkin | Classification,Pathologist evaluation | Central,Basis of Assessment,Pathologist evaluation | Central | Description,Administrative

Itemgroups: Central Pathology Assessment,Pathology Assessment Description,Administration

Itemgroups: Signed informed consent available for participation in the registry and consultation,Signed informed consent available for data transfer, data storage, and data handling ...,Storage of remaining bio material with contact for each scientific usage,Storage and use of remaining bio material for the following research projects (pseudonymized) for all NHL,Storage and use of remaining bio material for the following research projects (pseudonymized) FOR LYMPHOBLASTIC LYMPHOMA,Storage and use of remaining bio material for the following research projects (pseudonymized) FOR MATURE B-CELL LYMPHOMA,Storage and use of remaining bio material for the following research projects (pseudonymized) FOR LARGE CELL ANAPLASTIC LYMPHOMA (ALCL)

Itemgroup: Criteria

Itemgroups: Patient demographics,Therapy,Chemotherapy Regimen,Intrathecal therapy,Supportive therapy,Administration of medication,Comorbidity at the therapy begin,Medication duration,G-CSF,Cycle duration,Therapy discontinuation,Stem Cell Mobilization,Lab results prior to chemotherapy cycle,Lab results during interval after chemotherapy cycle,Toxicity,Intercurrent disease,Footer module

Itemgroups: Patient demographics,Therapy,Chemotherapy Regimen,Intrathecal therapy,Supportive therapy,Administration of medication,Comorbidity at the therapy begin,Medication duration,G-CSF,Cycle duration,Therapy discontinuation,Stem Cell Mobilization,Lab results prior to chemotherapy cycle,Lab results during interval after chemotherapy cycle,Toxicity,Intercurrent disease,Footer module

Itemgroups: Patient demographics,Therapy,Chemotherapy Regimen,Intrathecal therapy,Supportive therapy,Administration of medication,Comorbidity at the therapy begin,Medication duration,G-CSF,Cycle duration,Therapy discontinuation,Stem Cell Mobilization,Lab results prior to chemotherapy cycle,Lab results during interval after chemotherapy cycle,Toxicity,Hematopoietic Regeneration,Intercurrent disease,Footer module

Itemgroups: Patient demographics,Therapy,Chemotherapy Regimen,Intrathecal therapy,Supportive therapy,Administration of medication,Comorbidity at the therapy begin,Medication duration,G-CSF,Cycle duration,Therapy discontinuation,Stem Cell Mobilization,Lab results prior to chemotherapy cycle,Lab results during interval after chemotherapy cycle,Toxicity,Intercurrent disease,Footer module